NCT04011124已完成1 期
A Single Center, Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Rifampicin on Fluzoparib in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Area under the plasma concentration versus time curve (AUC) of Fluzoparib
研究概览
简要总结
The primary objective of the study was to assess the effect of repeated oral doses of Rifampicin on the pharmacokinetic profile of a single dose of Fluzoparib.
The secondary objective of the study was to assess the safety of Fluzoparib given alone versus Fluzoparib coadministered with Rifampicin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Sign the informed consent form before the trial and fully understand the trial content, process and possible adverse reactions;
- •Ability to complete the study as required by the protocol;
- •Age on the date of signing the informed consent form is 18 to 50 years old (including both ends) and is limited to male subjects only;
- •Male subjects are willing to have no birth plans in the next 6 months and voluntarily take effective contraception;
- •The fasting weight is not less than 50kg, and the body mass index (BMI) is in the range of 18 kg/m2 to 28 kg/m2 (including both ends);
- •Health status: no medical history of heart, liver, kidney, digestive tract, nervous system, mental abnormalities and metabolic abnormalities;
- •Accepted physical examination results (vital signs, physical examination) and routine laboratory examination (blood routine, blood biochemistry, urine routine, etc.), 12-lead ECG, X-chest, abdominal B-ultrasound, etc. or no clinical significance if abnormal.
- •Creatinine clearance (CLCr) ≥ 80 mL/min, and creatinine is less than or equal to the upper limit of normal
排除标准
- •Participate in blood donation within 3 months before screening and donate blood volume ≥400mL or blood loss ≥400mL, participate in blood donation within 1 month before screening and donate blood volume ≥200mL or blood loss ≥200mL, or receive blood transfusion;
- •Allergic constitution, including a history of severe drug allergy or drug allergy; a history of allergies to fluzoparib capsule or its excipients;
- •with drug and/or alcohol abuse history, or alcohol, nicotine and drug screening positives, or drug abuse in the past five years or used drugs 3 months before the trial; and could not prohibit smoking and alcohol during the trial period ;
- •with medical history of cardiovascular disease such as myocarditis, coronary heart disease, pathological arrhythmia, and stroke;
- •Pulmonary diseases, including invasive lung disease, pneumonia, dyspnea, etc.;
- •Chronic kidney disease, renal insufficiency, history of renal anemia;
- •have a history of dysphagia or any history of gastrointestinal disease that affects drug absorption;
- •any uncontrolled peptic ulcer, colitis, pancreatitis, etc.;
- •Anyone who has undergone any surgery within the first 6 months of screening; has undergone any surgery that affects gastrointestinal absorption (including gastrectomy, bowel resection, stomach reduction, etc.);
- •with acute disease that has been clinically determined by the investigator occurred within 1 month before screening;
- •Other important organ diseases such as the nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolic and musculoskeletal system with clear medical history (such as uncontrolled diabetes, high blood pressure, etc.), enabling investigators considered unsuitable for participation in the study;
- •Those who have taken any clinical trial drugs within 3 months;
- •Take any drug that affects liver metabolism within 28 days before taking the investigational drug;
- •Take any prescription or over-the-counter medication within 14 days before taking the investigational drug;
- •Take any vitamin products or herbs within 14 days before taking the investigational drug;
- •Clinical laboratory tests are abnormal and clinically significant, or other clinical findings indicate the following diseases, including but not limited to gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular disease;
- •combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection;
- •The subject refused to discontinue any beverage containing methylxanthine, such as caffeine (coffee, tea, cola, chocolate, etc.) or alcoholic beverages or any juice, 48 hours before the investigational drug was administered until the end of the study;
- •Strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.;
- •The investigator believes that the subjects are not eligible to participate in this trial.
研究组 & 干预措施
Rifampicin + Fluzoparib
Experimental
干预措施: Fluzoparib (Drug)
Rifampicin + Fluzoparib
Experimental
干预措施: Rifampicin (Drug)
结局指标
主要结局
Area under the plasma concentration versus time curve (AUC) of Fluzoparib
时间窗: Day 1 to Day 15
Peak Plasma Concentration (Cmax) of Fluzoparib
时间窗: Day 1 to Day 15
次要结局
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)(Up to Day 22)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on FamitinibHealthy Adult SubjectsNCT04494659Jiangsu HengRui Medicine Co., Ltd.21
已完成
1 期
The Effect of Intermittent Rifampicin on RaltegravirHIVTuberculosisNCT01424826Helen Reynolds18
撤回
1 期
Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy ParticipantsHealthy ParticipantsNCT04558216Phathom Pharmaceuticals, Inc.
已完成
1 期
Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796HealthyNCT00384280Wyeth is now a wholly owned subsidiary of Pfizer24
已完成
1 期
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerHematologic MalignancyMalignant LymphomaNCT01324323Celgene14